Warren Botnick, MD
PSS Clinical Research
Warren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia. He is the Medical Director of the Critical Care Unit at DeKalb Medical Center in Decatur, Medical Director of Southern Sleep Technologies and the Co-Director of two sleep disorders centers in the Atlanta area, and was one of the founders of Cogent Healthcare, among the first national hospitalist corporations. Dr. Botnick is a principal investigator in research studies on PAH, pulmonary embolism, deep vein thrombosis, asthma, sepsis, pneumonia, and chronic obstructive pulmonary disease. He has lectured around the country on topics in pulmonary, critical care, and sleep medicine, and around the world to GLG clients on the marketplace for products in these fields. Dr. Botnick has consulted for companies such as Pfizer, GlaxoSmithKline, Jazz, and Ortho-McNeil. He also has served as a consultant to a privately-held corporation distributing and marketing home respiratory and sleep equipment. (This is me - Update Profile)
| 2005 - present | President PSS Clinical Research |
|---|---|
| 2003 - present | Partner Pulmonary & Sleep Specialists |
| 2000 - present | Medical Director Southern Sleep Technologies, Inc. |
GLG Study Groups with Warren Botnick, MD(?)
| Study Group Name | Members |
|---|---|
| Sleep Physicians (US) | 119 |
| Physicians who Treat Primary Pulmonary Hypertension (US) | 81 |
| Physicians who Treat Insomnia (US) | 508 |
| Physicians who Treat Asthma (US) | 442 |
GLG NewsSM Analyses by Warren Botnick, MD(?)
Eicosanoids appear promising in the treatment of such airways diseases as COPD and asthma, which affect millions worldwide. Any alternative to current anti-inflammatory therapy, which consists almost entirely of forms of corticosteroids, would almost certainly be welcomed and adopted in widespread...
Cephalosporins have been standard therapy for pneumonia for many years, but to date this class of drug has been ineffective against MRSA. Ceftobiprole appears to represent a breakthrough in this regard. I would expect the drug to be well tolerated and, for the most part, to cause few major...
Though the potential international market for eszopiclone is large, interest in the product among sleep specialists in the US has leveled off. Its success internationally may well depend more on distancing the product from other agents such as the Ambien "family," a decidedly difficult task, and...
These data help strengthen the growing perception that oral agents in general, direct thrombin inhibitors in particular, and perhaps specifically dabigatran, represent the future of anticoagulation therapy. Safety data are of paramount importance, given the prior failure of ximelagatran in this...
GLG InstituteSM Seminars with Warren Botnick, MD(?)
Recent Seminars
Request a project with Warren Botnick, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms